Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.
Zeng Z, Qian X, Liu F, Wang Y, Yuan Y, Fang C, Zhang X, Yuan S, Chen R, Yu B, Wang T, Yin Y, Li Y, Liu A.
Zeng Z, et al. Among authors: yuan s, yuan y.
Front Immunol. 2023 Sep 6;14:1269596. doi: 10.3389/fimmu.2023.1269596. eCollection 2023.
Front Immunol. 2023.
PMID: 37744366
Free PMC article.